Last reviewed · How we verify
AR-301
AR-301 is a monoclonal antibody that targets and neutralizes Pseudomonas aeruginosa exotoxin A to reduce bacterial virulence and enhance immune clearance in respiratory infections.
AR-301 is a monoclonal antibody that targets and neutralizes Pseudomonas aeruginosa exotoxin A to reduce bacterial virulence and enhance immune clearance in respiratory infections. Used for Cystic fibrosis with Pseudomonas aeruginosa respiratory infection, Ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
At a glance
| Generic name | AR-301 |
|---|---|
| Also known as | AR-301 (tosatoxumab) |
| Sponsor | Aridis Pharmaceuticals, Inc. |
| Drug class | Monoclonal antibody (anti-virulence) |
| Target | Pseudomonas aeruginosa exotoxin A |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
AR-301 binds to Pseudomonas aeruginosa exotoxin A, a major virulence factor secreted by the bacterium that inhibits protein synthesis and promotes bacterial survival. By neutralizing this toxin, the drug reduces bacterial pathogenicity and allows the host immune system to more effectively control the infection. This approach is designed to work synergistically with standard antibiotics and the patient's innate immune response.
Approved indications
- Cystic fibrosis with Pseudomonas aeruginosa respiratory infection
- Ventilator-associated pneumonia caused by Pseudomonas aeruginosa
Common side effects
- Infusion-related reactions
- Immunogenicity/anti-drug antibodies
Key clinical trials
- Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 (PHASE3)
- Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AR-301 CI brief — competitive landscape report
- AR-301 updates RSS · CI watch RSS
- Aridis Pharmaceuticals, Inc. portfolio CI